Os et thérapies moléculaires ciblées: Nouveaux agents

Translated title of the contribution: Bone targeted therapies: New agents

Claire Barth, Christophe Massard, Stéphane Vignot

    Research output: Contribution to journalArticlepeer-review

    3 Citations (Scopus)

    Abstract

    The development of bisphosphonates and anti-RANK/RANKL agents was associated with a better understanding of physiological and pathological processes of bone remodeling. New agents are now developed in this context targeting factors associated with osteoclastogenesis (TGFβ, PTHrP), with signaling pathways activated during bone remodeling (Src, Cathepsin K) or with tumor cells homing into bone (chemokines). This review aims to present the underlying rationale for these developments as well as the clinical results. The emergence of new bone targeting therapies is discussed.

    Translated title of the contributionBone targeted therapies: New agents
    Original languageFrench
    Pages (from-to)1215-1221
    Number of pages7
    JournalBulletin du Cancer
    Volume100
    Issue number11
    DOIs
    Publication statusPublished - 1 Jan 2013

    Cite this